Equal HIV-1 decay kinetics in HSV-2-infected and HSV-2-uninfected clinical trial participants treated with antiretroviral therapy.

TitleEqual HIV-1 decay kinetics in HSV-2-infected and HSV-2-uninfected clinical trial participants treated with antiretroviral therapy.
Publication TypeJournal Article
Year of Publication2012
AuthorsSchouten JThomas, Schiffer JT
JournalJ Acquir Immune Defic Syndr
Volume60
Issue1
Pagination68-71
Date Published2012 May 1
ISSN1944-7884
KeywordsAdult, Anti-HIV Agents, Antiretroviral Therapy, Highly Active, Coinfection, Female, Herpes Genitalis, Herpesvirus 2, Human, HIV Infections, HIV-1, Humans, Male, Middle Aged, Treatment Outcome, Viral Load
Abstract

Herpes simplex virus-2 increases HIV-1 viral load and may augment HIV-1 transmission probability. To test the hypothesis that lower HIV-1 clearance rates in HSV-2-infected persons may account for this higher HIV-1 viral load, we studied 149 participants from 3 ACTG viral dynamic studies (A315, A5160s, and A5166s). Though HIV-1 viral load was 0.19 logs higher in HSV-2-positive versus HSV-2-negative persons, first and second phase clearance rates during antiretroviral therapy were equal between participants in these 2 groups.

DOI10.1097/QAI.0b013e31824bed3f
Alternate JournalJ. Acquir. Immune Defic. Syndr.
PubMed ID22330608
PubMed Central IDPMC3331968
Grant ListAI069434 / AI / NIAID NIH HHS / United States
K23 AI087206 / AI / NIAID NIH HHS / United States
K23 AI087206 / AI / NIAID NIH HHS / United States
K23 AI087206-03 / AI / NIAID NIH HHS / United States
U01 AI068636 / AI / NIAID NIH HHS / United States
U01 AI069434 / AI / NIAID NIH HHS / United States
U01 AI069434-06 / AI / NIAID NIH HHS / United States
U01 AI68634 / AI / NIAID NIH HHS / United States
UM1 AI068634 / AI / NIAID NIH HHS / United States
UM1 AI068634-06 / AI / NIAID NIH HHS / United States
UM1 AI068636-06 / AI / NIAID NIH HHS / United States